Steps toward nebulization in-use studies to understand the stability of new biological entities [0.03%]
进行雾化使用研究以了解新型生物制剂稳定性的步骤
Carlos Victor Montefusco-Pereira
Carlos Victor Montefusco-Pereira
The need for novel biological drugs against respiratory diseases has been highlighted during the Coronavirus (COVID-19) pandemic. The use of inhalation presents challenges to drug product stability, which is especially true for delivery usi...
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five [0.03%]
基于五规则前后产品发布的小分子口服药物研发和产品开发的趋势分析
Sven Stegemann,Chris Moreton,Sami Svanbäck et al.
Sven Stegemann et al.
In 1997, the 'Rule of Five' (Ro5) suggested physicochemical limitations for orally administered drugs, based on the analysis of chemical libraries from the early 1990s. In this review, we report on the trends in oral drug product developmen...
Strategizing the human microbiome for small molecules: Approaches and perspectives [0.03%]
小分子视角下的人体微生物组策略：方法和展望
Aehtesham Hussain,Umera Patwekar,Dattatray S Mongad et al.
Aehtesham Hussain et al.
Studies of the human microbiome are providing a deeper understanding of its significance to human health, and increasing evidence links the microbiota with several diseases. Nevertheless, the exact mechanisms involved in human-microbe inter...
Alaa A A Aljabali,Rasha M Bashatwah,Mohammad A Obeid et al.
Alaa A A Aljabali et al.
Given their superior efficacy, rapid engineering, low-cost manufacturing, and safe delivery prospects, mRNA vaccines offer an intriguing alternative to conventional vaccination technologies. Several mRNA vaccine platforms targeting infectio...
Metabolomics- and systems-biology-guided discovery of metabolite lead compounds and druggable targets [0.03%]
基于代谢组学和系统生物学的代谢产物先导化合物和可药用靶点的发现
Amelia Palermo
Amelia Palermo
Metabolomics enables the comprehensive and unbiased analysis of metabolites and lipids in biological systems. In conjunction with high-throughput activity screening, big data and synthetic biology, metabolomics can guide the discovery of le...
Alexander Schuhmacher,Naomi Haefner,Katharina Honsberg et al.
Alexander Schuhmacher et al.
Digital health and digital pharma are considered supportive tools for patients and healthcare providers (HCPs), making the market highly attractive for industry players. Not surprisingly, Tech Giants have started to move into this area. We ...
Small biotechs versus large pharma: Who drives first-in-class innovation in oncology? [0.03%]
小型生物技术公司与大型制药公司：谁在肿瘤学领域引领原创性创新？
Kate H Kennedy,Krisstel Gomez,Natalie J Thovmasian et al.
Kate H Kennedy et al.
There is a narrative that large pharma relies on biotech and academia for drug innovation. We tested this thesis by identifying the originators of all 50 first-in-class (FIC) oncology drugs that were approved by the FDA from 2010 through 20...
Yuze Sheng,Zhongjian Chen,Wei Wu et al.
Yuze Sheng et al.
Biofilms are colonies of microorganisms that are embedded in autocrine extracellular polymeric substances (EPS), imparting antibiotic resistance and recalcitrant bacterial infection. Nanoparticles (NPs) can enhance the biofilm inhibition an...
Rafaela Zimmermann,Bruna Borstmann Jardim Leal,Daikelly Iglesias Braghirolli et al.
Rafaela Zimmermann et al.
In the constant search for the development of more-specific and more-selective drugs, especially with regard to the challenge of encapsulating hydrophilic molecules, polymer nanotechnologies are remarkable for their biocompatible and biodeg...
Expanding therapeutic strategies for intracellular bacterial infections through conjugates of apoptotic body-antimicrobial peptides [0.03%]
通过凋亡小体-抗菌肽结合物扩大治疗细胞内细菌感染的治疗策略
Valentina Nieto Marín,Danieli Fernanda Buccini,Jorge W Arboleda V et al.
Valentina Nieto Marín et al.
Macrophage intracellular infections are difficult to treat because conventional antibiotics tend to have poor penetration of mammalian cells. As a consequence, the immune response is affected and bacteria remain protected inside macrophages...